An Orally Active Allosteric GLP-1 Receptor Agonist Is Neuroprotective in Cellular and Rodent Models of Stroke
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Diabetes is a major risk factor for the development of stroke. Glucagon-like peptide-1 receptor (GLP-1R) agonists have been in clinical use for the treatment of diabetes and also been reported to be neuroprotective in ischemic stroke. The quinoxaline 6,7-dichloro-2-methylsulfonyl-3-N-tert- butylaminoquinoxaline (DMB) is an agonist and allosteric modulator of the GLP-1R with the potential to increase the affinity of GLP-1 for its receptor. The aim of this study was to evaluate the neuroprotective effects of DMB on transient focal cerebral ischemia. In cultured cortical neurons, DMB activated the GLP-1R, leading to increased intracellular cAMP levels with an EC50 value about 100 fold that of exendin-4. Pretreatment of neurons with DMB protected against necrotic and apoptotic cell death was induced by oxygen-glucose deprivation (OGD). The neuroprotective effects of DMB were blocked by GLP-1R knockdown with shRNA but not by GLP-1R antagonism. In C57BL/6 mice, DMB was orally administered 30 min prior to middle cerebral artery occlusion (MCAO) surgery. DMB markedly reduced the cerebral infarct size and neurological deficits caused by MCAO and reperfusion. The neuroprotective effects were mediated by activation of the GLP-1R through the cAMP-PKA-CREB signaling pathway. DMB exhibited anti-apoptotic effects by modulating Bcl-2 family members. These results provide evidence that DMB, a small molecular GLP-1R agonist, attenuates transient focal cerebral ischemia injury and inhibits neuronal apoptosis induced by MCAO. Taken together, these data suggest that DMB is a potential neuroprotective agent against cerebral ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, activation of GLP-1R leads to an increase in cAMP levels, which in turn activates PKA, a widely regulating enzyme of cellular functions, capable of phosphorylating a variety of target proteins, thereby initiating the PKA/CREB signaling pathway.326,327”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [326]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182456d46 · Cited by 1,512
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000442015.53336.12 · Cited by 1,408 · cited 1×
“Ischemic stroke is a leading cause of adult morbidity and mortality worldwide with very limited treatment options [1].”
BackgroundBederson, J. B., Pitts, L. H., Germano, S. M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. M. (1986) · Stroke · doi:10.1161/01.str.17.6.1304 · Cited by 1,277 · cited 1×
“After evaluation of neurological deficits, the infarct volume was measured by TTC staining, which has been widely used for accurately reflecting the extent of irreversible ischemic damage in cerebral tissues [20].”
MethodKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062 · cited 1×
“Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide secreted from the L-cells of the small intestine [2].”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 1×
“GLP-1 exerts its effects by binding to GLP-1 receptor (GLP-1R), a member of the class B family of seven transmembrane G protein-coupled receptors (GPCRs) [3].”
BackgroundDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837 · cited 1×
“To further evaluate the mechanism, we exposed the cells to exendin (9–39) (1 μM), an orthosteric competitive antagonist [23, 24].”
BackgroundLi, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 1×
“found that intracerebral administration of exendin-4 induced neuroprotection and locomotor activity after stroke in the rat, and showed this neuroprotective effect was mediated by GLP-1R in GLP-1R knockout mice [4].”
BackgroundThorens, B., Porret, A., Bühler, L., Deng, S.-P., Morel, P., & Widmann, C. (1993) · Diabetes · doi:10.2337/diab.42.11.1678 · Cited by 558
Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors
Hoare, S. R. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03370-2 · Cited by 379 · cited 1×
“GLP-1R activation by peptide agonists requires binding predominantly to the large N-terminal domain of the receptor [34].”
BackgroundPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Nakka, V. P., Gusain, A., & Raghubir, R. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9110-5 · Cited by 282
Small-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232 · cited 2×
“DMB has been shown to potentially increase the affinity of peptide agonists [25].”
BackgroundTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Manandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198 · cited 2×
“These GLP-1 mimetics possess favorable pharmacokinetic properties, including reduced frequency of injections and improved glycemic control throughout the day [9, 10].”
BackgroundPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 1×
“GLP-1 and analogues cross the blood-brain barrier, protect memory formation or motor activity, enhance neurogenesis, reduce apoptosis, protect neurons from oxidative stress, and reduce chronic inflammation response [6, 7].”
BackgroundDing, L., & Jin, Z. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.149 · Cited by 165
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154
Apoptosis After Experimental Stroke: Fact or Fashion?
MacManus, J. P., & Buchan, A. M. (2000) · Journal of Neurotrauma · doi:10.1089/neu.2000.17.899 · Cited by 146 · cited 1×
“Apoptosis is suggested to be one of the leading contributors to neuronal injury after cerebral ischemia [30, 31].”
BackgroundAshabi, G., Khodagholi, F., Khalaj, L., Goudarzvand, M., & Nasiri, M. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-013-9475-2 · Cited by 131
Darsalia, V., Mansouri, S., Ortsäter, H., Olverling, A., Nozadze, N., Kappe, C., Iverfeldt, K., Tracy, L. M., Grankvist, N., Sjöholm, Å., et al. (2012) · Clinical Science · doi:10.1042/cs20110374 · Cited by 130 · cited 2×
“Exendin-4 was reported to confer neuroprotective effect in a MCAOmodel of diabetic rats [14].”
BackgroundSairanen, T., Karjalainen-Lindsberg, M.-L., Paetau, A., Ijäs, P., & Lindsberg, P. J. (2006) · Brain · doi:10.1093/brain/awh645 · Cited by 123
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122 · cited 2×
“widely expressed in many regions of the brain [32, 33].”
BackgroundNeuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120
Hyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118
de Maturana, R. L., Willshaw, A., Kuntzsch, A., Rudolph, R., & Donnelly, D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212147200 · Cited by 105 · cited 1×
“Exendin (9–39) blocked the effects of GLP-1 by competitively binding the extracellular domain of the GLP-1R [24, 42].”
BackgroundTurner, R. C., Dodson, S. C., Rosen, C. L., & Huber, J. D. (2013) · Journal of neurosurgery · doi:10.3171/2012.11.jns12408 · Cited by 98 · cited 1×
“Neuroprotective strategies aimed at decreasing brain damage after ischemic stroke have failed to be translated into the clinical setting along the past decades [43].”
BackgroundDarsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92
Green, C. J., Henriksen, T. I., Pedersen, B. K., & Solomon, T. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044284 · Cited by 80
Wu, F., Echeverry, R., Wu, J., An, J., Haile, W. B., Cooper, D. S., Catano, M., & Yepes, M. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.001 · Cited by 74
Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71
Hypoxia-inducible factor 1 contributes to N-acetylcysteine’s protection in stroke
Zhang, Z., Yan, J., Taheri, S., Liu, K. J., & Shi, H. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.11.007 · Cited by 71 · cited 1×
“The middle cerebral artery occlusion procedure was conducted as previously described [18].”
MethodChen, T., Wang, J., Li, C., Zhang, W., Zhang, L., An, L., Pang, T., Shi, X., & Liao, H. (2014) · Scientific Reports · doi:10.1038/srep05531 · Cited by 56 · cited 1×
“TUNEL staining was performed 24 h after MCAO as previously described [22].”
MethodSanderson, T. H., Kumar, R., Murariu-Dobrin, A. C., Page, A. B., Krause, G. S., & Sullivan, J. M. (2009) · Neurological Research · doi:10.1179/174313209x382449 · Cited by 55 · cited 1×
“Insulin was reported to confer a neuroprotective effect in cerebral ischemia in MCAO [44].”
BackgroundExperimental Models for Assaying Microvascular Endothelial Cell Pathophysiology in Stroke
Camós, S., & Mallolas, J. (2010) · Molecules · doi:10.3390/molecules15129104 · Cited by 49 · cited 1×
“OGD and reperfusion is an in vitro model that mimics the condition of ischemia-reperfusion injury [26].”
BackgroundWu, Z., Liu, S., Nair, I., Omori, K., Scott, S., Todorov, I., Shively, J. E., Conti, P. S., Li, Z., & KANDEEL, F. R. (2014) · Theranostics · doi:10.7150/thno.7759 · Cited by 47
Meloni, B. P., Majda, B. T., & Knuckey, N. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00396-7 · Cited by 47 · cited 1×
“OGD on primary neuronal cultures was performed as previously reported [17].”
MethodFu, L., & Wang, R. (2008) · Journal of Molecular Modeling · doi:10.1007/s00894-008-0372-2 · Cited by 46 · cited 1×
“However, DMB reportedly interacts with the GLP-1R at an allosteric site that has been speculated to be a cavity located near the transmembrane 5 and 6 region [41].”
BackgroundDarsalia, V., Larsson, M., Nathanson, D., Klein, T., Nyström, T., & Patrone, C. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.17 · Cited by 44
Kir6.1 Knockdown Aggravates Cerebral Ischemia/Reperfusion-Induced Neural Injury in Mice
Dong, Y., Wang, L., Huang, X., Cao, W., Lu, M., Ding, J., Sun, X., & Hu, G. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12117 · Cited by 33 · cited 1×
“The neurological deficit scores were evaluated in a blinded fashion 24 h after MCAO and reperfusion based on Bederson’s score standard [19].”
MethodSelf-citationPro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia
Zhang, H., Meng, J., Li, X., Zhou, S., Qu, D., Wang, N., Jia, M., Ma, X., & Xiaoxing, L. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.010 · Cited by 28 · cited 1×
“8 mm) 7 days before MCAO injury as previously described [21].”
MethodSelf-citationTzefos, M., Harris, K., & Brackett, A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q379 · Cited by 21 · cited 1×
“These GLP-1 mimetics possess favorable pharmacokinetic properties, including reduced frequency of injections and improved glycemic control throughout the day [9, 10].”
BackgroundImpaired Glucose Metabolism and Cerebrovascular Diseases
Tanné, D. (2008) · KARGER eBooks · doi:10.1159/000115190 · Cited by 20
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188
“Our findings are relevant beyond AD and PD, because systemically administered IRAs also show promise in treating other neurological conditions, most notably amyotrophic lateral sclerosis (ALS) [133, 134], stroke [100, 135-140], and traumatic brain injury (TBI) [141].”
BackgroundGLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, Ç., Küçüker, M. U., Solaroğlu, İ., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 134
“3 levels (131,154), decreasing inflammatory factors (147), altering cAMP-PKA-CREB signaling (128,129,131,154), inhibiting oxidative stress (129,134,135), increasing BDNF (144) and VEGF (146), increasing healthy and proliferating cell numbers (133,143) and microvessel density (136) (Table 4a).”
BackgroundSmall-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity
Fontana, P., Du, G., Zhang, Y., Zhang, H., Vora, S. M., Hu, J. J., Shi, M., Tufan, A. B., Healy, L. B., Xia, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.08.007 · Cited by 139
Self-citationProtective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Metadata
- Authors
- Zhang, H., Liu, Y., Guan, S., Qu, D., Wang, L., Wang, X., Li, X., Zhou, S., Zhou, Y., Wang, N., Meng, J., & Ma, X.
- Affiliations
- Air Force Medical University (CN)
- Corresponding author
- Meng, Jingru
- Ma, Xue
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-02-10
- Volume
- 11
- Issue
- 2
- Pages
- e0148827
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4749391
- OpenAlex
- W2265017848
- Cited by
- 50
- References
- 44
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 8 · 2017: 5 · 2016: 1
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81402931, 81471093, 81571278)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor, allosteric agonists, DMB, neuroprotection, cerebral ischemia, ischemic stroke, middle cerebral artery occlusion, oxygen-glucose deprivation, neuronal apoptosis, cAMP/PKA/CREB signaling, Bcl-2 family proteins, oral administration, diabetes mellitus
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Allosteric Regulation, Animals, Blood Glucose, Brain, Cell Survival, Cells, Cultured, Drug Evaluation, Preclinical, Insulin, Male, Mice, Inbred C57BL, Neurons, Peptides, Quinoxalines, Sulfones, Venoms, Reperfusion Injury, Apoptosis, Neuroprotective Agents, Inhibitory Concentration 50, Infarction, Middle Cerebral Artery, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.